Addiction Science & Clinical Practice (Nov 2024)

Barriers and facilitators to medication-assisted treatment for cocaine use disorder among men who have sex with men: a qualitative study

  • Elaine Hsiang,
  • Kishan Patel,
  • Erin C. Wilson,
  • Alexandrea Dunham,
  • Janet Ikeda,
  • Tim Matheson,
  • Glenn-Milo Santos

DOI
https://doi.org/10.1186/s13722-024-00515-0
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background Rates of cocaine use disorder (CUD) among men who have sex with men (MSM) are high and rising. Among MSM, cocaine use is associated with negative socioeconomic, medical, and psychological outcomes. There are no FDA-approved pharmacotherapy options to treat CUD, and psychosocial interventions demonstrate limited efficacy. While there have been numerous trials evaluating possible medications for CUD, there is a scarcity of qualitative data on the barriers and facilitators of medication-assisted treatment. Methods Semi-structured interviews were conducted with 16 participants enrolled in a phase II randomized control trial evaluating extended-release lorcaserin among MSM with CUD. Participants were asked about their motivations for enrolling in the study, attitudes towards taking a medication for CUD, barriers and facilitators of study pill adherence, and their general study experience. Interviews were analyzed using an inductive and exploratory approach to thematic analysis. Results Participants were highly motivated to reduce cocaine use and viewed pharmacotherapy as a viable and desirable treatment option. Pharmacotherapy was seen as having fewer access and adherence structural barriers compared to existing psychosocial therapies. Medication reminders facilitated pill taking, while side effects, travel, and active substance use presented barriers to study pill adherence. Disclosure of study participation within social networks was variable pointing to anticipated substance use and treatment stigma. Conclusions Our study highlights important factors affecting the acceptability and uptake of medication-assisted treatment for CUD among a diverse sample of MSM. These findings can help guide the development and implementation of future pharmacotherapy options for CUD and other substance use disorders in this key population.

Keywords